Document is current
Any future updates will be listed below
-
Authors
van den Dorpel, Jan J. A.
Faraguna, Martha C.
Verdijk, Robert M.
van der Beek, Nadine A. M. E.
Pijnappel, W. W. M. Pim
van der Ploeg, Ans T.
van den Hout, Johanna M. P. https://orcid.org/0000-0001-8091-263X
-
Funding
Funding for this research was provided by:
Prinses Beatrix Spierfonds (W.TR19-02)
LSH-TKI (LSHM16008)
- License Information
-
More Information
Article History
Received: 7 May 2026
Revised: 29 June 2026
Accepted: 1 July 2026
First Online: 31 July 2026
Declarations
Conflicts of interest: A.T. v. d. P., J.M.P. v. d. H. and N.A.M.E van der Beek received funding for research, clinical trials, and/or as advisor from various industries working on ERT or next-generation therapies in the field of Pompe disease under agreements with Erasmus MC University Medical Center. PWWMP is co-founder and unpaid Chief Scientific Officer of LentiCure, a company developing gene therapy for lysosomal disorders including Pompe disease. The other authors declare no competing interests.
